Biohaven Financial Statements
NYSE: BHVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
12.08+0.15 (+1.26%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Biohaven revenue and earnings
Biohaven reported a net loss of $738.8 million, compared with a loss of $846.4 million a year earlier. Diluted earnings per share came in at -$6.86.
Summary generated from market data by MetaCap's automated system. Methodology
Biohaven income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Operating Expenses | — | — | — | 567.93M | 218.90M | 114.51M |
| Research & Development | 635.07M | 795.87M | 373.28M | 437.07M | 181.49M | 98.46M |
| Operating Income | -745.38M | -885.11M | -436.05M | -567.93M | -218.90M | -114.51M |
| Other Income (Expense) | 8.00M | 39.42M | 26.50M | -1.91M | 6.47M | -4.16M |
| Pretax Income | -737.38M | -845.69M | -409.55M | -569.84M | -212.43M | -118.67M |
| Income Tax | 1.44M | 735.00K | -1.38M | 438.00K | 1.37M | 0 |
| Net Income | -738.82M | -846.42M | -408.17M | -570.28M | -213.80M | -118.67M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| EPS (Basic) | -6.86 | -9.28 | -5.73 | -12.75 | -5.43 | -3.01 |
| EPS (Diluted) | -6.86 | -9.28 | -5.73 | -12.75 | -5.43 | -3.01 |
| Shares Outstanding (Basic) | 107.62M | 91.23M | 71.20M | 44.74M | 39.38M | 39.38M |
| Shares Outstanding (Diluted) | 107.62M | 91.23M | 71.20M | 44.74M | 39.38M | 39.38M |
| EBITDA | -735.46M | -877.26M | -429.14M | -566.55M | -217.51M | -114.43M |
This table shows 6 annual periods of Biohaven's income statement, from FY 2025 back to FY 2020, across 12 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow BHVN's reporting calendar. What is a income statement?